1. Adler CH, Singer C, O’Brien C, Hauser RA, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089–95.
2. Axelrod J, Senoh S, Witkop B. O-methylation of catecholamines in vivo. J Biol Chem 1958;233:697-701.
3. Baas H, Beiske AG, Ghika J, Jackson M, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off“ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421–8.
4. Baas H, Zehrden F, Selzer R, Kohnen R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet 2001;40:383–93.
5. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50(Suppl 5):17–25.
6. Ceravolo R, Piccini P, Bailey DL, Jorga KM, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse 2002;43:201–7.
7. De Santi C, Giulianotti PC, Pietrabissa A, Mosca F, et al. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol 1998;54:215–9.
8. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2004;4:CD004553 (Review).
9. Dingemanse J, Jorga K, Zurcher G, Schmitt M, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253–62.
10. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508–17.
11. Doudet DJ, Chan GL, Holden JE, Pate BD, et al. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-dopa. Eur J Pharmacol 1997;334:31–8.
12. Dupont E, Burgunder JM, Findley LJ, Olsson JE, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov Disord 1997;12:928–34.
13. Factor SA. Parkinson’s disease: Motor fluctuations. Curr Treat Options Neurol 1999;1: 21–32.
14. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharm Rev 1975;27: 135–94.
15. Haasio K, Koponen A, Penttila KE, Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur J Pharmacol 2002;453:21–6.
16. Haasio K, Lounatmaa K, Sukura A. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp Toxicol Pathol 2002;54:9–14.
17. Haasio K, Nissinen E, Sopanen L, Heinonen EH. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J Neural Transm 2002;109:1391–401.
18. Holden JE, Doudet DJ, Endres CJ, Morrison KS, et al. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J Nucl Med 1997;38:1568–74.
19. Jorga K, Fotteler B, Banken L, Snell P, et al. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 2000;49:39–48.
20. Jorga K, Fotteler B, Heizmann P, Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 1999;48:513–20.
21. Jorga K, Fotteler B, Schmitt M, Nielsen T, et al. The effect of COMT-inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurology 1997:38:59–67.
22. Jorga K, Fotteler B, Sedek G, Nielsen T, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998;245:223–30.
23. Jorga KM, Larsen JP, Beiske A, Schleimer M, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999;6:211–9.
24. Jorga KM, Nicholl DJ. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). Br J Clin Pharmacol 1999;48:449–52.
25. Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998;50(Suppl 5):S31–8.
26. Karhunen T, Tilgmann C, Julkunen I, Ulmanen I, et al. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 1994;42:1079–90.
27. Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov Disord 2001;16:858–66.
28. Kurth MC, Adler CH, Hilaire MS, Singer C, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81–7.
29. Mannisto PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 1992;105:569–74.
30. Myllylä V, Jackson M, Larsen JP, Baas H. Efficacy and safety of tolcapone in levodopa treated Parkinson’s disease patients with wearing off phenomenon: a multicentre double-blind, randomized, placebo-controlled trial. Eur J Neurol 1997;4:333–41.
31. Napolitano A, Del Dotto P, Petrozzi L, Dell’Agnello G, et al. Pharmacokinetics and pharmacodynamics of L-dopa after acute and 6-week tolcapone administration in patients with Parkinson’s disease. Clin Neuropharmacol 1999;22:24–9.
32. Napolitano A, Zurcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 1995;273:215–21.
33. Nissinen E, Kaheinen P, Penttila KE, Kaivola J, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997;340:287–94.
34. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S1–88.
35. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar advisory panel. Arch Neurol 2000;57:263–7.
36. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, et al. Tolcapone improves motor function in parkinsonian patients with the „wearing-off“ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066–71.
37. Suchowersky O, Panisset M, Bailey P. Comparison of two different doses of tocapone in non-fluctuating Parkinson’ disease patients. Mov Disord 1998;13(Suppl 2):175.
38. The Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 2007;22:14–9.
39. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group. Mov Disord 1999;14:38–44.
40. Waters CH, Kurth M, Bailey P, Shulman LM, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997;49:665–71.
Priv.-Doz. Dr. med. Horst Baas, Klinik für Neurologie, Klinikum Stadt Hanau gGmbH, Leimenstraße 20, 63450 Hanau, E-Mail: Horst_Baas@klinikum-hanau.de